New Zealand markets closed

Statera Biopharma, Inc. (STAB)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00070.0000 (0.00%)
At close: 10:47AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 49.99k
Enterprise value 6.95M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.16
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.37

Trading information

Stock price history

Beta (5Y monthly) 281.36
52-week change 3-96.67%
S&P500 52-week change 322.38%
52-week high 30.0380
52-week low 30.0001
50-day moving average 30.0006
200-day moving average 30.0007

Share statistics

Avg vol (3-month) 324.69k
Avg vol (10-day) 34k
Shares outstanding 571.42M
Implied shares outstanding 671.42M
Float 848.11M
% held by insiders 10.00%
% held by institutions 10.00%
Shares short (30 Dec 2022) 4774.53k
Short ratio (30 Dec 2022) 40.39
Short % of float (30 Dec 2022) 41.65%
Short % of shares outstanding (30 Dec 2022) 41.42%
Shares short (prior month 30 Nov 2022) 4829.13k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Sept 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)-230.65%

Management effectiveness

Return on assets (ttm)-23.85%
Return on equity (ttm)-286.94%

Income statement

Revenue (ttm)3.69M
Revenue per share (ttm)0.08
Quarterly revenue growth (yoy)183.50%
Gross profit (ttm)N/A
EBITDA -20.58M
Net income avi to common (ttm)-91.83M
Diluted EPS (ttm)-2.3600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)506.1k
Total cash per share (mrq)0.01
Total debt (mrq)7.41M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.05
Book value per share (mrq)-0.20

Cash flow statement

Operating cash flow (ttm)-12.09M
Levered free cash flow (ttm)340.1k